林业发展局核准VONVENDI,用于预防和治疗Von Willebrand疾病患者所有年龄段的出血。 FDA approves VONVENDI for preventing and treating bleeding in von Willebrand Disease patients of all ages.

林业发展局扩大了对VONVENDI的核准范围,将常规预防成年人因Von Willebrand疾病(VWD)出血和对VWD儿童的按需治疗包括在内。 The FDA has expanded the approval of VONVENDI to include routine prevention of bleeding in adults with von Willebrand Disease (VWD) and on-demand treatment in children with VWD. VONVENDI是批准为成人和儿童提供的唯一重新组合的VWF替代疗法。 VONVENDI is the only recombinant VWF replacement therapy approved for both adults and children. 这份批准书有助于管理VWD患者的出血风险和日常生活负担。 This approval aids in managing bleeding risks and daily life burdens for VWD patients. 常见副作用包括头痛、呕吐、恶心、头晕和皮肤发痒。 Common side effects include headache, vomiting, nausea, dizziness, and itchy skin.